MA-LOADSPRING-SOLUTIONS
LoadSpring Solutions, a leading provider of global managed cloud solutions, announces a strategic collaboration with Google Cloud and SADA to provide clients with enhanced project analytics via Artificial Intelligence and Business Intelligence solutions. LoadSpring will combine its application, support, and project expertise with SADA's delivery expertise and Google Cloud infrastructure, solutions, and capabilities in AI and ML to help clients eliminate risks while increasing their insights and data access to make critical business and project decisions in real-time.
As a global leader in hosting, integrating, and providing access to software application data for project and asset-intensive organizations, LoadSpring recognizes the importance of access to a global technology footprint. Its customers operate worldwide and expect the same performance and support, whether in the Americas, Europe, the Middle East, or Pan-Asia. The new alliance will accelerate customer benefits, including one-stop managed cloud services, centralized support, and improved project command and control through LoadSpring Cloud Platform.
"The strategic alignment between our organizations is significant. The investments Google Cloud, SADA, and LoadSpring, are making to deliver best-in-class cloud solutions is transformational for our clients. I'm truly excited about the prospect of hosting, accessing, and leveraging years of data during the project life-cycle," said Dean Edmundson, Chief Strategy Officer at LoadSpring.
"Organizations today have an opportunity to transform business processes and derive more value out of their data with cloud capabilities in AI, ML, and analytics," said Dave Hutchison, Managing Director, Worldwide Channels at Google Cloud. "We are excited that LoadSpring and SADA will collaborate to help businesses leverage Google Cloud infrastructure and technologies to do so, and look forward to working together to drive digital transformation."
"We're excited to partner with LoadSpring to help them maximize the value of their Google Cloud investment," stated Simon Margolis, VP of CE, SADA. "The combined strength of our offerings will help clients expand their cloud, Business Intelligence, AI, and ML capabilities to achieve better project results."
ABOUT LOADSPRING
Founded in 1999, LoadSpring is a global cloud solutions provider obsessed with offering the highest level of managed cloud services. LoadSpring delivers expert Project Management solutions and fast access to project data, Business Intelligence, and hundreds of best-of-breed project-based applications. Data safety is assured through their SOC 2 Type II security certification, providing an impenetrable cloud environment. Through their proprietary LoadSpring Cloud Platform and their soon-to-be-launched LoadSpring Marketplace, customers and partners get effortless app provisioning, higher productivity, and ROI – all while reducing the burden on their IT departments.
ABOUT SADA
SADA is a leading global provider of business and technology services empowering people to transform their work, their organizations, and the world. SADA teams have helped enterprise clients in healthcare, media, entertainment, retail, manufacturing, and the public sector achieve their boldest ambitions and solve their most complex problems. A Google Cloud Partner with multiple Specializations, SADA delivers continuous innovation, strong partnerships, and service excellence. This has led to numerous accolades and awards, including the Google Cloud Global Reseller Partner of the Year for 2018 and 2019, the Inc. 5000 Honoree list of America's Fastest Growing Private Companies for 14 straight years, and the 2020 Inc. list of America's Top 50 Workplaces. More info at www.sada.com .
For more information, contact Stacey Witt at switt@loadspring.com or visit www.loadspring.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005791/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom